Watchdog bans online pharmacy’s hormone testing ads
In Business
Follow this topic
Bookmark
Record learning outcomes
The Advertising Standards Authority (ASA) has upheld complaints concerning five ads for online pharmacy Voy’s low testosterone testing service, finding that several of the promotions exaggerated the link between hormone levels and certain symptoms.
Published today (November 18), the ASA ruling concerns four poster ads and two Facebook ads from Menwell Ltd, which trades as Voy.
The first poster featured large print stating “It’s not him, it’s his hormones” with smaller print stating “Low sex drive? Lost his spark? He might have low testosterone. Get an at-home test.”
The other posters the ASA received complaints about featured similar messaging linking fatigue and irritability to low testosterone.
Meanwhile, the first Facebook ad included the message “Low testosterone sneaks up on 1 in 4 men over 30” and presented five symptoms “to look out for,” while the second featured television personality Jason Fox and stated “Low energy”; “no motivation”; “Anxiety”; and “Loss of strength & muscle mass,” linking these symptoms to low testosterone.
Complaints received about the poster campaign “challenged whether the ads misleadingly attributed low testosterone to a range of common symptoms with many potential causes,” said the ASA.
The ASA brought its own challenges against the Facebook ads on similar grounds, also challenging whether the claim “Low testosterone sneaks up on 1 in 4 men over 30” in the first of these ads was misleading.
Voy responded by saying the ads used language that was “deliberately conditional” and did not claim any of the conditions mentioned were “definitively caused” by low testosterone.
To back up the ‘one in four’ claim, Voy presented a study that it said found that 24 per cent of 1,475 men surveyed had testosterone levels below clinical thresholds.
The ASA found that three of the poster ads and the second Facebook ad included “exaggerated” claims about the link between low testosterone and symptoms like fatigue and irritability as these are considered “non-specific” symptoms, although it acknowledged that the ads presented these connections in conditional terms.
It found that the “Low sex drive?” poster did not “materially exaggerate” the connection as there is a stronger evidence base linking libido to testosterone levels.
The ASA also upheld its complaint concerning the ‘one in four’ claim in the first Facebook ad, finding that the claim had not been “adequately substantiated” as the study Voy cited excluded men who had not already shown symptoms of androgen deficiency.
The company was told it may not use three of the four poster ads or either of the Facebook ads in their current form.
Voy has been the subject of several ASA rulings this year, including one earlier this month banning an ad the watchdog said promoted prescription oral weight loss tablets to the public and one in May that concerned Black Friday GLP-1 promotions.
Dr Earim Chaudry, Voy's chief medical officer, said: "Every patient decision at Voy is clinician-led and these campaigns were developed to align with UK advertising standards. We keep all our advertising under continual review to ensure it meets any updated guidance.
"We actioned withdrawal of the adverts while the investigation was under way and will not run it again. We cooperated fully with the ASA throughout and acted promptly on its feedback.
"We have an established relationship with the ASA, working with them on individual matters and proactively on the wider regulatory landscape. We believe working collaboratively as this fast-evolving area develops will ensure patients are protected and can safely access appropriate care."
Related: Online pharmacy warned over testosterone blood testing ads